Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients

Hoffman, Thijs W.; Meek, Bob; Rijkers, Ger T.; Kessel, Diana A. van

doi:10.1016/j.trim.2022.101599

Cited by 11 publications

(15 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly in SOT recipients with previous SARS-CoV-2 infection, anti-RBD IgG responses were comparable to that in controls. In line with our finding, previous studies showed that SARS-CoV-2 infection before or after vaccination boosts the humoral immune response and elicits broader immunity than vaccination alone (13,29,30,49). In our study, only 15% of SOT recipients received the vaccine doses, and the proportions of participants with previous SARS-CoV-2 infection were comparable between SOT recipients and controls.…”

Section: Discussionsupporting

confidence: 91%

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

et al. 2023

View full text Add to dashboard Cite

IntroductionWe investigated humoral and T-cell responses within 12 months after first BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received at least three vaccine doses. Furthermore, we compared the immune response in participants with and without previous SARS-CoV-2 infection.MethodsWe included adult liver, lung, and kidney transplant recipients, and controls were selected from a parallel cohort of healthcare workers.ResultsAt 12th-month, the IgG geometric mean concentrations (GMCs) (P<0.001), IgA GMCs (P=0.003), and median IFN-γ (P<0.001) were lower in SOT recipients than in controls. However, in SOT recipients and controls with previous infection, the neutralizing index was 99%, and the IgG, and IgA responses were comparable. After adjustment, female-sex (aOR: 3.6, P<0.009), kidney (aOR: 7.0, P= 0.008) or lung transplantation (aOR: 7.5, P= 0.014), and use of mycophenolate (aOR: 5.2, P=0.03) were associated with low IgG non response. Age (OR:1.4, P=0.038), time from transplantation to first vaccine (OR: 0.45, P<0.035), and previous SARS-CoV-2 infection (OR: 0.14, P<0.001), were associated with low IgA non response. Diabetes (OR:2.4, P=0.044) was associated with T-cell non response.ConclusionIn conclusion, humoral and T-cell responses were inferior in SOT recipients without previous SARS-CoV-2 infection but comparable to controls in SOT recipients with previous infection.

show abstract

Section: Discussionsupporting

confidence: 91%

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 5 , 6 , 7 , 8 , 9 , 10 , 11 Previous studies showed that around half of solid organ recipients who were non-responders to the second dose seroconverted after a third mRNA vaccine dose, given as booster. 12 , 13 , 14 , 15 However, only few studies have determined the effectiveness of a third vaccine dose in LTR, 16 , 17 and markers predictive of vaccine response are still lacking. In order to quantify the impact of immunosuppression on vaccine response and hopefully to predict response or nonresponse, one should be able to quantify the level of immunosuppression.…”

Section: Introductionmentioning

confidence: 99%

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients

Gallais

Picard

Solis

et al. 2022

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…In contrast, in a small study population, Havlin et al showed impaired humoral responses to the third dose (13%), despite detectable specific T cells responses [ 24 ]. In the study published by Hoffman et al, a humoral response after the third dose was detected in 62% LuTRs [ 25 ]. In the present study, a humoral response was detected in 22 of 24 (92%) LuTRs, with significantly higher antibody titers compared to those after the second dose.…”

Section: Discussionmentioning

confidence: 99%

Immune Response after mRNA COVID-19 Vaccination in Lung Transplant Recipients: A 6-Month Follow-Up

et al. 2022

View full text Add to dashboard Cite

Background and objective: This prospective cohort study analyzed the immune response to COVID-19 mRNA vaccines in lung transplant recipients (LuTRs) compared to healthy controls (HCs) at a 6-month follow-up. Methods: After the first two doses of either BNT162b2 or mRNA-1273, SARS-CoV-2 antibodies were measured in LuTRs (n = 57) and sex- and age-matched HCs (n = 57). Antibody kinetics during a 6-month follow-up and the effect of a third vaccine dose were evaluated. Humoral responses were assessed using the Elecsys® Anti-SARS-CoV-2 S immunoassay. In 16 LuTRs, SARS-CoV-2-specific T cell responses were quantified using IFN-γ ELISpot assays. Results: Seroconversion rates were 94% and 100% after the first and second vaccine dose, respectively, in HCs, while only 19% and 56% of LuTRs developed antibodies. Furthermore, 22 of 24 LuTRs who received the third vaccine dose showed seroconversion (five of seven primary non-responders and 17 of 17 primary responders). A T cell response against SARS-CoV-2-spike S1 and/or S2 was detected in 100% (16/16) of HCs and 50% (8/16) of LuTRs. Conclusions: The data suggest that LuTRs have reduced humoral and cellular immune responses after two doses of COVID-19 mRNA vaccination when compared to HCs. A third dose may be of substantial benefit.

show abstract

Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients

Cited by 11 publications

References 20 publications

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients

Immune Response after mRNA COVID-19 Vaccination in Lung Transplant Recipients: A 6-Month Follow-Up

Contact Info

Product

Resources

About